MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

A health cost analysis for Huntington disease in Peru

G. Silva-Paredes, M. Cornejo-Olivas, M. Inca-Martinez, K. Espinoza-Huertas, A. Vishnevetsky, P. Mazzetti, R. Urbanos-Garrido (Lima, Peru)

Meeting: 2016 International Congress

Abstract Number: 1150

Keywords: Familial neurodegenerative diseases

Session Information

Date: Wednesday, June 22, 2016

Session Title: Huntington's disease

Session Time: 12:00pm-1:30pm

Location: Exhibit Hall located in Hall B, Level 2

Objective: To estimate economic costs of caring for an individual with Huntington disease from the patients and caregivers perspective.

Background: Huntington disease (HD) is a devastating fatal neurodegenerative disorder that leads to progressive disability and eventually complete dependence. Caring for a patient with HD imposes a significant financial burden not only due to the costs of medications, but also due to transportation costs, housing adaptations, lost patient income, as well as lost caregiver income. The economic impact of HD in developing countries such as Peru, may be particularly devastating because of the limited social safety net, but little is known about the health costs of HD or other orphan diseases in these settings.

Methods: 97 HD patients and their accompanying caregivers participated in a survey on disease-associated costs. All participants completed a standardized questionnaire related to quality of life, work productivity, activities of daily living, and health care utilization. Direct costs were estimated using a prevalence approach, while indirect health costs were estimated based on human capital approach.

Results: 64% of patients were female, and the mean age in women was 50 years (SD=13.98), and 47 years (SD=13.2) in men. The mean monthly income per patient was $148.30 while the mean monthly household income was $620.30. The mean annual cost of HD is $9538.72 per patient, of which the direct non-health costs are 71.3% of the total, indirect costs are 22.6%, and direct health costs are 6.1%. The annual cost per patient increases with the degree of disability in the patients: patients with a Barthel 5 have an annual cost of $4150.12 US, $9775.36 for Barthel 4, $18,285.11 for Barthel 3, $24,192.21 for Barthel 2, and $24,961.37 for Barthel 1.

Conclusions: The economic impact of HD for families and patients in Peru is catastrophic, with the costs of the disease far surpassing the annual incomes of both patients and their families. It is thus vitally necessary for the state to prioritize economic support and health coverage for these patients and families.

To cite this abstract in AMA style:

G. Silva-Paredes, M. Cornejo-Olivas, M. Inca-Martinez, K. Espinoza-Huertas, A. Vishnevetsky, P. Mazzetti, R. Urbanos-Garrido. A health cost analysis for Huntington disease in Peru [abstract]. Mov Disord. 2016; 31 (suppl 2). https://www.mdsabstracts.org/abstract/a-health-cost-analysis-for-huntington-disease-in-peru/. Accessed September 21, 2023.
  • Tweet
  • Email
  • Print

« Back to 2016 International Congress

MDS Abstracts - https://www.mdsabstracts.org/abstract/a-health-cost-analysis-for-huntington-disease-in-peru/

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Patients with Essential Tremor Live Longer than their Relatives
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Carpal Tunnel Syndrome in Patients with Tremor
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • #23972 (not found)
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Patients with Essential Tremor Live Longer than their Relatives
  • #22892 (not found)
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Insulin dependent diabetes and hand tremor
  • Patients with Essential Tremor Live Longer than their Relatives
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2023 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley